Refeyn Launches KaritroMP for Rapid and Reproducible Characterization of Large Viral Vectors

Refeyn, a leader in mass photometry technology, announces the launch of its macro mass photometry platform, KaritroMP. This new benchtop instrument marks an evolutionary step beyond mass photometry, allowing for the characterization of large viral vectors, including adenovirus vectors (AdVs) and lentivirus vectors (LVVs). Offering fast, simple, and qualitative analysis, KaritroMP can inform the R&D of gene and cell therapies, and vaccines.

Unlike classical mass photometry technology, KaritroMP utilizes light scattering to measure both the size and contrast of single particles, allowing for large particles such as AdVs and LVVs to be characterized across two dimensions. Using these measurements, populations of similar size but with different masses can be resolved, enabling the analysis of the ratio of empty vs full AdV capsids, in addition to detection of any crude or degraded particles present. This provides essential data on viral vector characteristics, including stability, purity, and quality. Consequently, this approach can streamline viral vector process development and optimization, allowing users to easily and quickly compare different production and purification methods, and assess batch-to-batch variation.

Key advantages of the KaritroMP are its speed and ease of use. This benchtop instrument takes just six minutes to analyze a sample, and can do so autonomously with up to 13 samples using integrated custom-built software. The semiautomated workflow requires little sample, and with quick preparation steps and straightforward operation, the operational efficiency of analytical processes can be dramatically increased.

“We are very excited to announce the launch of the KaritroMP” states Matthias Langhorst, CPO at Refeyn. “With this new technology, large viral vectors can be characterized in a new way that is also easy to use and fast. We are looking forward to seeing our customers realize the benefits of this innovative analytical approach on the development of their cell and gene therapies and vaccines.”

The launch of this new platform exemplifies Refeyn’s commitment to pushing the boundaries of single particle analysis with its pioneering mass photometry technologies – supporting the biopharmaceutical industry and facilitating groundbreaking advancements. Enabling fast, simple, and reproducible analysis of single particles including viral vectors, Refeyn continues to pave the way for efficient and high-quality analytical workflows, to help streamline the process development of novel therapeutics.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Michael Dabrowski, CEO of Pelago Bioscience "We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.
The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.

By using this website you agree to accept Medical Device News Magazine Privacy Policy